



# NCI SBIR AND YOUR STATE:

## MASSACHUSETTS



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$128.4 million** in funding across **115 Phase II SBIR/STTR grants** to small businesses in Massachusetts. The following economic impact estimates quantify the program's contributions to the state's economy:



**\$629.1M**

**IN TOTAL DIRECT SALES**



**\$1.6B**

**IN TOTAL ECONOMIC IMPACT**



**6.7K**

**JOBS CREATED**



**\$55.3M**

**IN STATE & LOCAL TAXES COLLECTED**



**67**

**COMPANIES WITH SALES**

*\*These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in Massachusetts: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$374.8M in funding across all grants to oncology-focused small businesses in the state.*

### Success stories include:

#### **ALLEGRO DIAGNOSTICS, INC.**

Allegro developed a first-of-its-kind bronchial test for lung cancer using SBIR funding. The company was acquired by Veracyte for \$21 million and the product is now commercially available under trade name Percepta™.

#### **QUANTERIX CORPORATION**

Upon receiving Phase I NCI SBIR funding in 2008, Quanterix developed and optimized its Single Molecule Array (Simoa™) technology for detecting and quantifying biomarkers that were previously difficult or impossible to measure. The company reported \$137.4 million in revenue for 2024.

**The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to [ncisbir@mail.nih.gov](mailto:ncisbir@mail.nih.gov).**